PTC Therapeutics Q3 2024: Revenue Up Slightly, Assets Top $1.6B

TL;DR

PTCT Q3 revenue $76.95M vs $75.71M last year. Assets $1.6B.

AI Summary

PTC Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported total assets of $1.6 billion as of September 30, 2024. For the three months ended September 30, 2024, total revenues were $76.95 million, compared to $75.71 million for the same period in 2023.

Why It Matters

This filing provides investors with an update on PTC Therapeutics' financial performance and asset base, crucial for assessing the company's stability and growth prospects in the pharmaceutical sector.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, PTC Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

• $1.6B — Total Assets (As of September 30, 2024, indicating the company's overall financial resources.)
• $76.95M — Q3 2024 Revenue (Represents the company's top-line performance for the third quarter of 2024.)
• $75.71M — Q3 2023 Revenue (Provides a year-over-year comparison for the third quarter revenue.)

Key Players & Entities

• PTC THERAPEUTICS, INC. (company) — Filer
• 500 WARREN CORPORATE CENTER DRIVE (location) — Business Address
• WARREN (location) — City
• NJ (location) — State
• 07059 (location) — ZIP Code
• $1.6 billion (dollar_amount) — Total Assets as of September 30, 2024
• $76.95 million (dollar_amount) — Total Revenues for Q3 2024
• $75.71 million (dollar_amount) — Total Revenues for Q3 2023

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share PTCT Nasdaq Glo

Filing Documents

• tmb-20240930x10q.htm (10-Q) — 2820KB
• tmb-20240930xex31d1.htm (EX-31.1) — 11KB
• tmb-20240930xex31d2.htm (EX-31.2) — 10KB
• tmb-20240930xex32d1.htm (EX-32.1) — 6KB
• tmb-20240930xex32d2.htm (EX-32.2) — 6KB
• 0001070081-24-000023.txt ( ) — 14124KB
• tmb-20240930.xsd (EX-101.SCH) — 86KB
• tmb-20240930_cal.xml (EX-101.CAL) — 81KB
• tmb-20240930_def.xml (EX-101.DEF) — 419KB
• tmb-20240930_lab.xml (EX-101.LAB) — 804KB
• tmb-20240930_pre.xml (EX-101.PRE) — 640KB
• tmb-20240930x10q_htm.xml (XML) — 3050KB

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION

Financial Statements (unaudited)

Item 1. Financial Statements (unaudited) 4

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 42

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 63

Controls and Procedures

Item 4. Controls and Procedures 63

—OTHER INFORMATION

PART II—OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 63

Risk Factors

Item 1A. Risk Factors 63

Other Information

Item 5. Other Information 64

Exhibits

Item 6. Exhibits 65 i Table of Contents

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "might," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements in this Quarterly Report on Form 10-Q include, among other things, statements about: our ability to negotiate, secure and maintain adequate pricing, coverage and reimbursement terms and processes on a timely basis, or at all, with third-party payors for our products or product candidates that we commercialize or may commercialize in the future; our ability to maintain our conditional marketing authorization for Translarna TM (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy, or nmDMD, in the European Economic Area, or EEA, including our expectations with respect to the European Commission's potential adoption of the Committee for Medicinal Products for Human Use's negative opinion for the conditional marketing authorization for Translarna for the treatment of nmDMD following a reexamination procedure, or our ability to identify other potential mechanisms by which we may provide Translarna to nmDMD patients in the EEA; our ability to maintain our marketing authorizations in other jurisdictions in which Translarna has been approved; our ability to utilize results from Study 041 and from our international drug registry stu

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. PTC Therapeutics, Inc. Consolidated Balance Sheets (unaudited) In thousands (except shares) September 30, December 31, 2024 2023 Assets Current assets: Cash and cash equivalents $ 526,001 $ 594,001 Marketable securities 487,356 282,738 Trade and royalty receivables, net 199,976 160,822 Inventory, net 35,671 30,577 Prepaid expenses and other current assets 32,546 150,491 Total current assets 1,281,550 1,218,629 Fixed assets, net 63,175 87,089 Intangible assets, net 330,368 379,497 Goodwill 82,341 82,341 Operating lease ROU assets 59,465 91,896 Deposits and other assets 25,337 36,246 Total assets $ 1,842,236 $ 1,895,698 Liabilities and stockholders' deficit Current liabilities: Accounts payable and accrued expenses $ 336,346 $ 391,983 Deferred revenue — 801 Operating lease liabilities- current 14,113 13,002 Finance lease liabilities- current 2,642 3,000 Liability for sale of future royalties- current 257,611 194,314 Total current liabilities 610,712 603,100 Long-term debt 285,106 284,213 Contingent consideration payable 22,000 36,300 Deferred tax liability 55,909 55,905 Operating lease liabilities- noncurrent 82,770 97,627 Finance lease liabilities- noncurrent 15,574 17,184 Liability for sale of future royalties- noncurrent 1,824,440 1,619,783 Other long-term liabilities 77 141 Total liabilities 2,896,588 2,714,253 Stockholders' deficit: Common stock, $ 0.001 par value. Authorized 250,000,000 shares; issued and outstanding 76,952,124 shares at September 30, 2024. Authorized 250,000,000 shares; issued and outstanding 75,708,889 shares at December 31, 2023. 76 75 Additional paid-in capital 2,530,902 2,466,233 Accumulated other comprehensive loss ( 4,343 ) ( 1,285 ) Accumulated deficit ( 3,580,987 ) ( 3,283,578 ) Total stockholders' deficit ( 1,054,352 ) ( 818,555 ) Total

Notes to Consolidated Financial Statements (unaudited)

Notes to Consolidated Financial Statements (unaudited) September 30, 2024 In thousands (except share and per share amounts unless otherwise noted) 1. The Company PTC Therapeutics, Inc. (the "Company" or "PTC") is a global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. The Company's ability to innovate to identify new therapies and to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines. The Company's mission is to provide access to best-in-class treatments for patients who have little to no treatment options. The Company's strategy is to leverage its strong scientific and clinical expertise and global commercial infrastructure to bring therapies to patients. The Company believes that this allows it to maximize value for all its stakeholders. The Company has a diversified therapeutic portfolio pipeline that includes several commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy ("DMD"), a rare, life-threatening disorder. Translarna has marketing authorization in the European Economic Area (the "EEA") for the treatment of nonsense mutation Duchenne muscular dystrophy ("nmDMD") in ambulatory patients aged two years and older. Translarna also has marketing authorization in Russia for the treatment of nmDMD in patients aged two years and older and in Brazil for the treatment of nmDMD in ambulatory patients two years and older and for continued treatment of patients that become non-ambulatory

View Full Filing

View this 10-Q filing on SEC EDGAR